Amgen (NASDAQ:AMGN) Rating Increased to Hold at Barclays

NodeGuardian · 2026-03-06T04:10:50+00:00

Barclays upgraded Amgen to a "hold" rating amid varied analyst opinions. With strong earnings exceeding expectations and a target price of $351.76, the consensus remains a "Moderate Buy," projecting optimism for FY 2026.

NodeGuardian

2026-03-06 04:10:50

Abstract generation in progress

Barclays has upgraded Amgen (NASDAQ:AMGN) to a “hold” rating, as reported by Zacks.com. This upgrade comes amidst a mixed landscape of analyst ratings for Amgen, with an average target price of $351.76 and a consensus of “Moderate Buy.” The company recently reported strong earnings, beating analyst expectations, and has set optimistic guidance for FY 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.